Pharmaceutically inhibiting the FAM enzyme PLA2G4A increased expressions of NKG2D ligands in leukemia cells, thus enhancing NK cell-mediated cytotoxicity against leukemia cells. This evidence concerns the gene PLA2G4A and leukemia.